C048P: Galiximab Biosimilar, Anti-human CD80 Monoclonal Antibody

Catalog No.: C048P | **Product Name:** Galiximab Biosimilar, CD80 Monoclonal Antibody

Galiximab Biosimilar, CD80 Monoclonal Antibody. The research grade Galiximab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.

PRODUCT SPECIFICATIONS

Catalog No.	C048P
Product Name	Galiximab Biosimilar, CD80 Monoclonal Antibody
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	Cluster of differentiation 80, CD80, B7-1, B7, B7.1, BB1, CD28LG, CD28LG1, LAB7
Summary	Recombinant Humanized IgG1 Monoclonal Antibody.
Isotype	Humanized IgG1.
Source/Host	The anti-human CD80 monoclonal antibody galiximab biosimilar was produced in mammalian cells.
Specificity/Sensitivity	The research grade galiximab biosimilar specifically binds to the human CD80.
Applications	ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by galiximab.
Form Of Antibody	0.2 μM filtered solution, pH 6.0, no stabilizers or preservatives.
Endotoxin	<1 EU/mg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	The research grade galiximab biosimilar is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Note	The research grade Galiximab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.

REFERENCES & BACKGROUND

What is Galiximab biosimilar research grade? Galiximab Biosimilar uses the same protein sequences as the therapeutic antibody galiximab. A humanized IgG1 monoclonal antibody directed against CD80, the natural ligand for the T-cell antigen CD28 which mediates T-cell and B-cell adhesion. Galiximab binds to CD80 expressed on the cell surfaces of follicular lymphomas, resulting in antibody-dependent cell-mediated cytotoxicity (ADCC). CD80 is expressed on activated B-cells and gamma-interferon-stimulated monocytes and is often expressed at low levels on the surfaces of follicular lymphoma cells and other lymphoid malignancies. Galiximab, an IgG(1) anti-CD80 antibody, binds to CD80, a costimulatory molecule involved in T-cell activation. Reduction in lesional, activated T cells induces improvement in psoriatic plaques.